Balance Sheet
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInventory AverageInvested Capital

Ascendis Pharma A (ASND) Debt to Equity (2021 - 2025)

Ascendis Pharma A's Debt to Equity history spans 3 years, with the latest figure at -$4.32 for Q4 2023.

  • For Q4 2023, Debt to Equity fell 330.27% year-over-year to -$4.32; the TTM value through Dec 2023 reached -$4.32, down 330.27%, while the annual FY2023 figure was -$4.32, 330.27% down from the prior year.
  • Debt to Equity for Q4 2023 was -$4.32 at Ascendis Pharma A, down from $1.88 in the prior quarter.
  • Across five years, Debt to Equity topped out at $1.88 in Q4 2022 and bottomed at -$4.32 in Q4 2023.
  • The 3-year median for Debt to Equity is $0.12 (2021), against an average of -$0.78.
  • The largest annual shift saw Debt to Equity soared 1481.09% in 2022 before it tumbled 330.27% in 2023.
  • A 3-year view of Debt to Equity shows it stood at $0.12 in 2021, then surged by 1481.09% to $1.88 in 2022, then crashed by 330.27% to -$4.32 in 2023.
  • Per Business Quant, the three most recent readings for ASND's Debt to Equity are -$4.32 (Q4 2023), $1.88 (Q4 2022), and $0.12 (Q4 2021).